

PRODUCT INFORMATION

Common Name	IMMU-132, hRS7-SN-38, hRS7-SN-38-ADC, hRS7-[CL-SN-38], hrS7-SN-38, Unconjugated mAb
Conjugate	Unconjugated
Synonyms	TACSTD2;GA733-1;M1S1;TROP2
Applications	ELISA; Flow Cyt
Recommended Dilutions	ELISA 1:5000-10000; Flow Cyt 1:100
Formulation & Reconstitution	Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
Host Species	Humanized
IgG type	Human IgG1 - kappa
Reactivity	Human
Target	Trop2
Uniprot ID	P09758
Description	Anti-Trop2 (sacituzumab biosimilar) mAb
Delivery	In Stock
Storage & Shipping	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
Background	Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals. Our unconjugated biosimilar monoclonal antibodies (mAbs) are based on the sequences outlined in relevant patents or scientific publications. These antibodies are in their native, unconjugated form, meaning they do not contain any payload or therapeutic agent attached. They are designed for use in research and development, and their performance has been tested as standalone molecules through comprehensive QC tests.
Usage	Research use only
DIMA Disclaimer	All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement.



**Anti-Trop2 (sacituzumab govitecan biosimilar) mAb ELISA**  
0.2 µg of Trop2, mFc-His Tagged protein per well




Figure 1. ELISA plate pre-coated by 2 µg/ml (100 µl/well) Human Trop2, mFc-His tagged protein PME100501 can bind Anti-Trop2 Neutralizing antibody in a linear range of 0.13-16.0 ng/ml.




Figure 2. Flow cytometry analysis of antigen binding of anti-human Trop2 mAb(BME100023).  
(A) BME100023 does not bind to 293T cells that do not express Trop2.  
(B) A clear peak shift of BME100023 was seen compared to the control when incubated with Trop2-expressing A431 cells, indicating strong binding of BME100023 to Trop2. Antibodies were incubated at 2 µg/mL.






Figure 3. HEK293 cell line transfected with irrelevant protein (B) and human Trop2 protein (A) were surface stained with anti-Trop2 neutralizing antibody 1 $\mu$ g/ml (sacituzumab) followed by Alexa 488-conjugated anti-human IgG secondary antibody.

